Global Generic Drugs Market By Revenue Model (Prescription Products, Over the Counter (OTC) Products); By Application (Respiratory, Dermatology, Oncology, Diabetes, Infectious diseases, Ophthalmology, Women’s Health, Central Nervous System (CNS), Cardiovascular, Urology, Others (Pain Management, etc.)); By Form (Tablets, Capsules, Injectables, Topical Creams, Others); By Distribution Channel (Retail Pharmacy, Hospital Pharmacy); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
The rise in multitude illnesses prevalent is leading to excessive expenditure on healthcare.
This trend has inflated demand for low cost and effective alternatives thus paving the pathway for entry of generic drugs in the mainstream pharmaceutical industry. The rise in healthcare awareness has inflated the frequency of healthcare treatments availed by individuals. Drugs are most commonly used method to treat illnesses and improve patient health. However, cost of these drugs is fuelled by the year-over-year increase in prices. Association for Accessible Medicines (AAM) states that brand-name drugs account for 77% of overall spending on prescription drugs, which has burdened the patients with pharmacy associated costs. These rises in healthcare prices have deprived half of the world’s population of standard health coverage. World Health Organization statistics states that about 800 million people spend at least 10% of their household budgets on healthcare expenses, which has pushed over 100 million people into extreme poverty. These factors have heightened the demand for alternative less costly generic and bio-similar drugs. Generic drugs are created similar to an existing brand-name drug which bare resemblance in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. The benefits associated with generic medicines showcasing similar clinical outcomes as that of its brand-name version and lower development costs have attracted investments from high number of market players. The Food and Drug Administration agency of U.S states that generic drugs cost 30% to 80% less than their brand-name counterparts. These benefits of generic drugs to efficiently tackle the rising healthcare associated costs are driving the growth of generic drugs market across the globe.
The drastic transformations in the lifestyle of global population, affecting the diet and daily activities, has negative implications on their health. The sedentary lifestyle with minimal movement of urban dwellers is a major reason for prevalence of non-communicable chronic illnesses such as heart disease, cancer, diabetes, and chronic respiratory diseases. The upsurge in chronic illnesses has worsening effects on health of global population. World Health Organization estimates that these non-communicable diseases are responsible for deaths of around 41 million people each year across the globe, which is equivalent to 71% of all deaths. The spread of these diseases from prosperous economies to unprivileged economies has further bolstered the number of patients. Diseases such as cardiovascular disease, hypertension, diabetes, and cancer impose 80% of their burden on low and middle income economies. This prevalence of chronic illnesses amongst populations across continents has created an upsurge in the demand for low cost generic medicines. Access to these affordable generic medications assists humans to improve medication adherence, which leads to overall better health outcomes. Moreover, generic drug manufacturers are also capitalising on this opportunity. For instance, in May 2018, Glenmark Pharma launched generic version of asthma drug ‘Seretide Accuhaler’ in Denmark. Other companies such as Cipla Inc. and Lupin have also launched their generic version of asthma drugs. Similar strategic investments by prominent pharmaceutical giants are fuelling the growth of generic drugs market, globally.
The recent outbreak of COVID-19 pandemic is anticipated to create nourishing environment for generic drugs. The governments of countries affected by coronavirus outbreak have imposed lockdowns to avoid the spread of this disease which in-turn has hampered the supply chains of medical supplies creating a shortfall in brand-name drugs from international suppliers. This crisis has posed locally made generic medicines as the potential alternative. Also, drug manufacturers are inventing generic version of drugs used in treatment of active COVID-19 patients to reduce the overall treatment costs. For instance, in June 2020, Cipla Inc. announced launch of generic version of Gilead Sciences Inc.’s ‘Remdesivir’ drug which is approved by U.S Food and Drug Administration agency for treatment of COVID-19. These on-going efforts to cater the shortfall of drugs through generic versions are anticipated create high demand in global generic drugs market over the forecast years.
The transformation of global customer requirements and shopping habits has created an inclination towards online channels. The emerging trend of on-demand medicine services and e-pharmacies are anticipated to inflate the demand for generic drugs. For instance, StayHappi Pharmacy announced launch of its online medicine stores which delivers affordable generic drugs at the doorstep of the customers. These emerging trends are anticipated pose lucrative growth opportunities in global generic drugs market in future years.
Application Outlook:
Chronic illnesses such as diabetes, cardiovascular and respiratory diseases are having high prevalence in world’s population and demand high expenditure on regular medications to avoid occurrences of strokes. Cardiovascular diseases are ranked the as most common reason of death by World Health Organization which takes a toll of 17.9 million lives annually. From the total expenditure associated with treatment of cardiovascular diseases, high share is dedicated to the drugs, owing to the high frequency of medicine refills required to maintain optimal health conditions. This has created a high demand for affordable generic medicines and attracted active interest of market players. For instance, Mylan, Sandoz and other players have launched generic drugs for cardiovascular diseases. This growing attention of market players towards chronic illnesses are propelling their share in global generic drugs market.
Form Outlook:
Oral medications such as tablets and capsules held a dominant share of global generic drugs market in 2018 owing to the ease of replication compared to specialized drugs including sterile injectables. Also the high number of oral solid drugs going off-patent according to the list published by Food and Drug Administration agency of U.S in 2018 creates a high potential opportunities for generic drugs manufacturers to cash-on. These factors have contributed towards dominance of solid oral generic drugs such as tablets and capsules and created future growth opportunities.
Regional Outlook:
North America region registered the highest share in global generic drugs market in 2018. The rate of generic drugs prescribed by the medical practitioners is high in the region with a rate of 9 out of 10 generic drugs prescriptions in U.S. As per a report published by Association for Accessible Medicines (AAM) in 2019, generic medicines saved US$ 293 billion in 2018 from a total of 4 billion generic drug prescriptions in U.S. Also, the high availability of affordable generic drugs has further assisted the growth of generic drugs market in North America.
In terms of revenue, global generic drugs market was valued at US$ 284.56 Bn in 2018 and is anticipated to reach 472.32 Bn by 2027, growing at a CAGR of 5.8% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Generic Drugs Market Revenue & Forecast, (US$ Million), 2013 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of generic drugs market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the generic drugs market are Abbott Laboratories, Allergan, Inc., Alvion Pharmaceuticals P.C., Amneal Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited., AstraZeneca plc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Egis Group, Eli Lilly and Company, Endo International plc, Fresenius Kabi (Kabi SwissBioSim GmbH), Gedeon Richter Ltd, Gilead Sciences, Inc., GlaxoSmithKline Plc., Lupin Pharmaceuticals, Inc., Mylan N.V., Novartis International AG, Pfizer Inc., STADA Arzneimittel AG, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd. amongst others.
Global Generic Drugs Market:
By Type
- Prescription Products
- Over the Counter (OTC) Products
By Application
- Respiratory
- Dermatology
- Oncology
- Diabetes
- Infectious diseases
- Ophthalmology
- Women’s Health
- Central Nervous System (CNS)
- Cardiovascular
- Urology
- Others (Pain Management, etc.)
By Form
- Tablets
- Capsules
- Injectables
- Topical Creams
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Generic Drugs Market
6. Market Synopsis:
Generic Drugs Market
7. Generic Drugs Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Generic Drugs Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Generic Drugs Market
7.6. Porter’s
Five Force Analysis
7.7. Analysis on Impact of Covid-19 on Global Generic Drugs Market
8. Global Generic Drugs Market Analysis and Forecasts, 2019 –
2027
8.1. Overview
8.1.1. Global
Generic Drugs Market Revenue (US$ Mn)
8.2. Global
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Prescription
Products
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2013 – 2018
8.2.1.3. Market Forecast, 2019 – 2027
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2013 – 2018
8.2.1.5.1.2. Market Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2013 – 2018
8.2.1.5.2.2. Market Forecast, 2019 – 2027
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2013 – 2018
8.2.1.5.3.2. Market Forecast, 2019 – 2027
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2013 – 2018
8.2.1.5.4.2. Market Forecast, 2019 – 2027
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2013 – 2018
8.2.1.5.5.2. Market Forecast, 2019 – 2027
8.2.2. Over the
Counter (OTC) Products
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2013 – 2018
8.2.2.3. Market Forecast, 2019 – 2027
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2013 – 2018
8.2.2.5.1.2. Market Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2013 – 2018
8.2.2.5.2.2. Market Forecast, 2019 – 2027
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2013 – 2018
8.2.2.5.3.2. Market Forecast, 2019 – 2027
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2013 – 2018
8.2.2.5.4.2. Market Forecast, 2019 – 2027
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2013 – 2018
8.2.2.5.5.2. Market Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Generic Drugs Market Analysis and Forecasts, 2019 –
2027
9.1. Overview
9.2. Global
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Respiratory
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2013 – 2018
9.2.1.3. Market Forecast, 2019 – 2027
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2013 – 2018
9.2.1.5.1.2. Market Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2013 – 2018
9.2.1.5.2.2. Market Forecast, 2019 – 2027
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2013 – 2018
9.2.1.5.3.2. Market Forecast, 2019 – 2027
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2013 – 2018
9.2.1.5.4.2. Market Forecast, 2019 – 2027
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2013 – 2018
9.2.1.5.5.2. Market Forecast, 2019 – 2027
9.2.2. Dermatology
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2013 – 2018
9.2.2.3. Market Forecast, 2019 – 2027
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2013 – 2018
9.2.2.5.1.2. Market Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2013 – 2018
9.2.2.5.2.2. Market Forecast, 2019 – 2027
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2013 – 2018
9.2.2.5.3.2. Market Forecast, 2019 – 2027
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2013 – 2018
9.2.2.5.4.2. Market Forecast, 2019 – 2027
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2013 – 2018
9.2.2.5.5.2. Market Forecast, 2019 – 2027
9.2.3. Oncology
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2013 – 2018
9.2.3.3. Market Forecast, 2019 – 2027
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2013 – 2018
9.2.3.5.1.2. Market Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2013 – 2018
9.2.3.5.2.2. Market Forecast, 2019 – 2027
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2013 – 2018
9.2.3.5.3.2. Market Forecast, 2019 – 2027
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2013 – 2018
9.2.3.5.4.2. Market Forecast, 2019 – 2027
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2013 – 2018
9.2.3.5.5.2. Market Forecast, 2019 – 2027
9.2.4. Diabetes
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2013 – 2018
9.2.4.3. Market Forecast, 2019 – 2027
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2013 – 2018
9.2.4.5.1.2. Market Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2013 – 2018
9.2.4.5.2.2. Market Forecast, 2019 – 2027
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2013 – 2018
9.2.4.5.3.2. Market Forecast, 2019 – 2027
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2013 – 2018
9.2.4.5.4.2. Market Forecast, 2019 – 2027
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2013 – 2018
9.2.4.5.5.2. Market Forecast, 2019 – 2027
9.2.5. Infectious
diseases
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2013 – 2018
9.2.5.3. Market Forecast, 2019 – 2027
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market Estimation, 2013 – 2018
9.2.5.5.1.2. Market Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2013 – 2018
9.2.5.5.2.2. Market Forecast, 2019 – 2027
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market Estimation, 2013 – 2018
9.2.5.5.3.2. Market Forecast, 2019 – 2027
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market Estimation, 2013 – 2018
9.2.5.5.4.2. Market Forecast, 2019 – 2027
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market Estimation, 2013 – 2018
9.2.5.5.5.2. Market Forecast, 2019 – 2027
9.2.6. Ophthalmology
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2013 – 2018
9.2.6.3. Market Forecast, 2019 – 2027
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market Estimation, 2013 – 2018
9.2.6.5.1.2. Market Forecast, 2019 – 2027
9.2.6.5.2. Europe
9.2.6.5.2.1. Market Estimation, 2013 – 2018
9.2.6.5.2.2. Market Forecast, 2019 – 2027
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market Estimation, 2013 – 2018
9.2.6.5.3.2. Market Forecast, 2019 – 2027
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market Estimation, 2013 – 2018
9.2.6.5.4.2. Market Forecast, 2019 – 2027
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market Estimation, 2013 – 2018
9.2.6.5.5.2. Market Forecast, 2019 – 2027
9.2.7. Women’s
Health
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2013 – 2018
9.2.7.3. Market Forecast, 2019 – 2027
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market Estimation, 2013 – 2018
9.2.7.5.1.2. Market Forecast, 2019 – 2027
9.2.7.5.2. Europe
9.2.7.5.2.1. Market Estimation, 2013 – 2018
9.2.7.5.2.2. Market Forecast, 2019 – 2027
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market Estimation, 2013 – 2018
9.2.7.5.3.2. Market Forecast, 2019 – 2027
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market Estimation, 2013 – 2018
9.2.7.5.4.2. Market Forecast, 2019 – 2027
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market Estimation, 2013 – 2018
9.2.7.5.5.2. Market Forecast, 2019 – 2027
9.2.8. Central
Nervous System (CNS)
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2013 – 2018
9.2.8.3. Market Forecast, 2019 – 2027
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market Estimation, 2013 – 2018
9.2.8.5.1.2. Market Forecast, 2019 – 2027
9.2.8.5.2. Europe
9.2.8.5.2.1. Market Estimation, 2013 – 2018
9.2.8.5.2.2. Market Forecast, 2019 – 2027
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market Estimation, 2013 – 2018
9.2.8.5.3.2. Market Forecast, 2019 – 2027
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market Estimation, 2013 – 2018
9.2.8.5.4.2. Market Forecast, 2019 – 2027
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market Estimation, 2013 – 2018
9.2.8.5.5.2. Market Forecast, 2019 – 2027
9.2.9. Cardiovascular
9.2.9.1. Definition
9.2.9.2. Market Estimation and Penetration, 2013 – 2018
9.2.9.3. Market Forecast, 2019 – 2027
9.2.9.4. Compound Annual Growth Rate (CAGR)
9.2.9.5. Regional Bifurcation
9.2.9.5.1. North America
9.2.9.5.1.1. Market Estimation, 2013 – 2018
9.2.9.5.1.2. Market Forecast, 2019 – 2027
9.2.9.5.2. Europe
9.2.9.5.2.1. Market Estimation, 2013 – 2018
9.2.9.5.2.2. Market Forecast, 2019 – 2027
9.2.9.5.3. Asia Pacific
9.2.9.5.3.1. Market Estimation, 2013 – 2018
9.2.9.5.3.2. Market Forecast, 2019 – 2027
9.2.9.5.4. Middle East and Africa
9.2.9.5.4.1. Market Estimation, 2013 – 2018
9.2.9.5.4.2. Market Forecast, 2019 – 2027
9.2.9.5.5. Latin America
9.2.9.5.5.1. Market Estimation, 2013 – 2018
9.2.9.5.5.2. Market Forecast, 2019 – 2027
9.2.10. Urology
9.2.10.1. Definition
9.2.10.2. Market Estimation and Penetration, 2013 – 2018
9.2.10.3. Market Forecast, 2019 – 2027
9.2.10.4. Compound Annual Growth Rate (CAGR)
9.2.10.5. Regional Bifurcation
9.2.10.5.1. North America
9.2.10.5.1.1.
Market Estimation, 2013 – 2018
9.2.10.5.1.2.
Market Forecast, 2019 – 2027
9.2.10.5.2. Europe
9.2.10.5.2.1.
Market Estimation, 2013 – 2018
9.2.10.5.2.2.
Market Forecast, 2019 – 2027
9.2.10.5.3. Asia Pacific
9.2.10.5.3.1.
Market Estimation, 2013 – 2018
9.2.10.5.3.2.
Market Forecast, 2019 – 2027
9.2.10.5.4. Middle East and Africa
9.2.10.5.4.1.
Market Estimation, 2013 – 2018
9.2.10.5.4.2.
Market Forecast, 2019 – 2027
9.2.10.5.5. Latin America
9.2.10.5.5.1.
Market Estimation, 2013 – 2018
9.2.10.5.5.2.
Market Forecast, 2019 – 2027
9.2.11. Others
9.2.11.1. Definition
9.2.11.2. Market Estimation and Penetration, 2013 – 2018
9.2.11.3. Market Forecast, 2019 – 2027
9.2.11.4. Compound Annual Growth Rate (CAGR)
9.2.11.5. Regional Bifurcation
9.2.11.5.1. North America
9.2.11.5.1.1.
Market Estimation, 2013 – 2018
9.2.11.5.1.2.
Market Forecast, 2019 – 2027
9.2.11.5.2. Europe
9.2.11.5.2.1.
Market Estimation, 2013 – 2018
9.2.11.5.2.2.
Market Forecast, 2019 – 2027
9.2.11.5.3. Asia Pacific
9.2.11.5.3.1.
Market Estimation, 2013 – 2018
9.2.11.5.3.2.
Market Forecast, 2019 – 2027
9.2.11.5.4. Middle East and Africa
9.2.11.5.4.1.
Market Estimation, 2013 – 2018
9.2.11.5.4.2.
Market Forecast, 2019 – 2027
9.2.11.5.5. Latin America
9.2.11.5.5.1.
Market Estimation, 2013 – 2018
9.2.11.5.5.2.
Market Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Generic Drugs Market Analysis and Forecasts, 2019 –
2027
10.1. Overview
10.2. Global
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Form
10.2.1. Tablets
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2013 – 2018
10.2.1.3. Market Forecast, 2019 – 2027
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1.
Market Estimation, 2013 – 2018
10.2.1.5.1.2.
Market Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1.
Market Estimation, 2013 – 2018
10.2.1.5.2.2.
Market Forecast, 2019 – 2027
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1.
Market Estimation, 2013 – 2018
10.2.1.5.3.2.
Market Forecast, 2019 – 2027
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1.
Market Estimation, 2013 – 2018
10.2.1.5.4.2.
Market Forecast, 2019 – 2027
10.2.1.5.5. Latin America
10.2.1.5.5.1.
Market Estimation, 2013 – 2018
10.2.1.5.5.2.
Market Forecast, 2019 – 2027
10.2.2. Capsules
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2013 – 2018
10.2.2.3. Market Forecast, 2019 – 2027
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1.
Market Estimation, 2013 – 2018
10.2.2.5.1.2.
Market Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1.
Market Estimation, 2013 – 2018
10.2.2.5.2.2.
Market Forecast, 2019 – 2027
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1.
Market Estimation, 2013 – 2018
10.2.2.5.3.2.
Market Forecast, 2019 – 2027
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1.
Market Estimation, 2013 – 2018
10.2.2.5.4.2.
Market Forecast, 2019 – 2027
10.2.2.5.5. Latin America
10.2.2.5.5.1.
Market Estimation, 2013 – 2018
10.2.2.5.5.2.
Market Forecast, 2019 – 2027
10.2.3. Injectables
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2013 – 2018
10.2.3.3. Market Forecast, 2019 – 2027
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1.
Market Estimation, 2013 – 2018
10.2.3.5.1.2.
Market Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1.
Market Estimation, 2013 – 2018
10.2.3.5.2.2.
Market Forecast, 2019 – 2027
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1.
Market Estimation, 2013 – 2018
10.2.3.5.3.2.
Market Forecast, 2019 – 2027
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1.
Market Estimation, 2013 – 2018
10.2.3.5.4.2.
Market Forecast, 2019 – 2027
10.2.3.5.5. Latin America
10.2.3.5.5.1.
Market Estimation, 2013 – 2018
10.2.3.5.5.2.
Market Forecast, 2019 – 2027
10.2.4. Topical
Creams
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2013 – 2018
10.2.4.3. Market Forecast, 2019 – 2027
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1.
Market Estimation, 2013 – 2018
10.2.4.5.1.2.
Market Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1.
Market Estimation, 2013 – 2018
10.2.4.5.2.2.
Market Forecast, 2019 – 2027
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1.
Market Estimation, 2013 – 2018
10.2.4.5.3.2.
Market Forecast, 2019 – 2027
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1.
Market Estimation, 2013 – 2018
10.2.4.5.4.2.
Market Forecast, 2019 – 2027
10.2.4.5.5. Latin America
10.2.4.5.5.1.
Market Estimation, 2013 – 2018
10.2.4.5.5.2.
Market Forecast, 2019 – 2027
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2013 – 2018
10.2.5.3. Market Forecast, 2019 – 2027
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1.
Market Estimation, 2013 – 2018
10.2.5.5.1.2.
Market Forecast, 2019 – 2027
10.2.5.5.2. Europe
10.2.5.5.2.1.
Market Estimation, 2013 – 2018
10.2.5.5.2.2.
Market Forecast, 2019 – 2027
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1.
Market Estimation, 2013 – 2018
10.2.5.5.3.2.
Market Forecast, 2019 – 2027
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1.
Market Estimation, 2013 – 2018
10.2.5.5.4.2.
Market Forecast, 2019 – 2027
10.2.5.5.5. Latin America
10.2.5.5.5.1.
Market Estimation, 2013 – 2018
10.2.5.5.5.2.
Market Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By Form
11. Global Generic Drugs Market Analysis and Forecasts, 2019 –
2027
11.1. Overview
11.2. Global
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.2.1. Retail
Pharmacy
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2013 – 2018
11.2.1.3. Market Forecast, 2019 – 2027
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1.
Market Estimation, 2013 – 2018
11.2.1.5.1.2.
Market Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1.
Market Estimation, 2013 – 2018
11.2.1.5.2.2.
Market Forecast, 2019 – 2027
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1.
Market Estimation, 2013 – 2018
11.2.1.5.3.2.
Market Forecast, 2019 – 2027
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1.
Market Estimation, 2013 – 2018
11.2.1.5.4.2.
Market Forecast, 2019 – 2027
11.2.1.5.5. Latin America
11.2.1.5.5.1.
Market Estimation, 2013 – 2018
11.2.1.5.5.2.
Market Forecast, 2019 – 2027
11.2.2. Hospital
Pharmacy
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2013 – 2018
11.2.2.3. Market Forecast, 2019 – 2027
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1.
Market Estimation, 2013 – 2018
11.2.2.5.1.2.
Market Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1.
Market Estimation, 2013 – 2018
11.2.2.5.2.2.
Market Forecast, 2019 – 2027
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1.
Market Estimation, 2013 – 2018
11.2.2.5.3.2.
Market Forecast, 2019 – 2027
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1.
Market Estimation, 2013 – 2018
11.2.2.5.4.2.
Market Forecast, 2019 – 2027
11.2.2.5.5. Latin America
11.2.2.5.5.1.
Market Estimation, 2013 – 2018
11.2.2.5.5.2.
Market Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By
Distribution Channel
12. North America Generic Drugs Market Analysis and Forecasts,
2019 - 2027
12.1. Overview
12.1.1. North
America Generic Drugs Market Revenue (US$ Mn)
12.2. North
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Prescription
Products
12.2.2. Over
the Counter (OTC) Products
12.3. North
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Respiratory
12.3.2. Dermatology
12.3.3. Oncology
12.3.4. Diabetes
12.3.5. Infectious
diseases
12.3.6. Ophthalmology
12.3.7. Women’s
Health
12.3.8. Central
Nervous System (CNS)
12.3.9. Cardiovascular
12.3.10. Urology
12.3.11. Others
12.4. North
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Form
12.4.1. Tablets
12.4.2. Capsules
12.4.3. Injectables
12.4.4. Topical
Creams
12.4.5. Others
12.5. North
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.1. Retail
Pharmacy
12.5.2. Hospital
Pharmacy
12.6. North
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.1.1.1. Prescription Products
12.6.1.1.2. Over the Counter (OTC) Products
12.6.1.2. U.S Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.1.2.1. Respiratory
12.6.1.2.2. Dermatology
12.6.1.2.3. Oncology
12.6.1.2.4. Diabetes
12.6.1.2.5. Infectious diseases
12.6.1.2.6. Ophthalmology
12.6.1.2.7. Women’s Health
12.6.1.2.8. Central Nervous System (CNS)
12.6.1.2.9. Cardiovascular
12.6.1.2.10.
Urology
12.6.1.2.11.
Others
12.6.1.3. U.S Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
12.6.1.3.1. Tablets
12.6.1.3.2. Capsules
12.6.1.3.3. Injectables
12.6.1.3.4. Topical Creams
12.6.1.3.5. Others
12.6.1.4. U.S Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.1.4.1. Retail Pharmacy
12.6.1.4.2. Hospital Pharmacy
12.6.2. Canada
12.6.2.1. Canada Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.2.1.1. Prescription Products
12.6.2.1.2. Over the Counter (OTC) Products
12.6.2.2. Canada Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.2.2.1. Respiratory
12.6.2.2.2. Dermatology
12.6.2.2.3. Oncology
12.6.2.2.4. Diabetes
12.6.2.2.5. Infectious diseases
12.6.2.2.6. Ophthalmology
12.6.2.2.7. Women’s Health
12.6.2.2.8. Central Nervous System (CNS)
12.6.2.2.9. Cardiovascular
12.6.2.2.10.
Urology
12.6.2.2.11.
Others
12.6.2.3. Canada Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
12.6.2.3.1. Tablets
12.6.2.3.2. Capsules
12.6.2.3.3. Injectables
12.6.2.3.4. Topical Creams
12.6.2.3.5. Others
12.6.2.4. Canada Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.2.4.1. Retail Pharmacy
12.6.2.4.2. Hospital Pharmacy
12.6.3. Mexico
12.6.3.1. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.3.1.1. Prescription Products
12.6.3.1.2. Over the Counter (OTC) Products
12.6.3.2. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.3.2.1. Respiratory
12.6.3.2.2. Dermatology
12.6.3.2.3. Oncology
12.6.3.2.4. Diabetes
12.6.3.2.5. Infectious diseases
12.6.3.2.6. Ophthalmology
12.6.3.2.7. Women’s Health
12.6.3.2.8. Central Nervous System (CNS)
12.6.3.2.9. Cardiovascular
12.6.3.2.10.
Urology
12.6.3.2.11.
Others
12.6.3.3. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
12.6.3.3.1. Tablets
12.6.3.3.2. Capsules
12.6.3.3.3. Injectables
12.6.3.3.4. Topical Creams
12.6.3.3.5. Others
12.6.3.4. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.3.4.1. Retail Pharmacy
12.6.3.4.2. Hospital Pharmacy
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Type
12.6.4.1.1. Prescription Products
12.6.4.1.2. Over the Counter (OTC) Products
12.6.4.2. Rest of North America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.4.2.1. Respiratory
12.6.4.2.2. Dermatology
12.6.4.2.3. Oncology
12.6.4.2.4. Diabetes
12.6.4.2.5. Infectious diseases
12.6.4.2.6. Ophthalmology
12.6.4.2.7. Women’s Health
12.6.4.2.8. Central Nervous System (CNS)
12.6.4.2.9. Cardiovascular
12.6.4.2.10.
Urology
12.6.4.2.11.
Others
12.6.4.3. Rest of North America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Form
12.6.4.3.1. Tablets
12.6.4.3.2. Capsules
12.6.4.3.3. Injectables
12.6.4.3.4. Topical Creams
12.6.4.3.5. Others
12.6.4.4. Rest of North America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
12.6.4.4.1. Retail Pharmacy
12.6.4.4.2. Hospital Pharmacy
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By Type
12.7.3. By
Application
12.7.4. By Form
12.7.5. By
Distribution Channel
13. Europe Generic Drugs Market Analysis and Forecasts, 2019 -
2027
13.1. Overview
13.1.1. Europe
Generic Drugs Market Revenue (US$ Mn)
13.2. Europe
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Prescription
Products
13.2.2. Over
the Counter (OTC) Products
13.3. Europe
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Respiratory
13.3.2. Dermatology
13.3.3. Oncology
13.3.4. Diabetes
13.3.5. Infectious
diseases
13.3.6. Ophthalmology
13.3.7. Women’s
Health
13.3.8. Central
Nervous System (CNS)
13.3.9. Cardiovascular
13.3.10. Urology
13.3.11. Others
13.4. Europe Generic
Drugs Market Revenue (US$ Mn) and Forecasts, By Form
13.4.1. Tablets
13.4.2. Capsules
13.4.3. Injectables
13.4.4. Topical
Creams
13.4.5. Others
13.5. Europe
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.1. Retail
Pharmacy
13.5.2. Hospital
Pharmacy
13.6. Europe
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.1.1.1. Prescription Products
13.6.1.1.2. Over the Counter (OTC) Products
13.6.1.2. France Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.1.2.1. Respiratory
13.6.1.2.2. Dermatology
13.6.1.2.3. Oncology
13.6.1.2.4. Diabetes
13.6.1.2.5. Infectious diseases
13.6.1.2.6. Ophthalmology
13.6.1.2.7. Women’s Health
13.6.1.2.8. Central Nervous System (CNS)
13.6.1.2.9. Cardiovascular
13.6.1.2.10.
Urology
13.6.1.2.11.
Others
13.6.1.3. France Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
13.6.1.3.1. Tablets
13.6.1.3.2. Capsules
13.6.1.3.3. Injectables
13.6.1.3.4. Topical Creams
13.6.1.3.5. Others
13.6.1.4. France Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.1.4.1. Retail Pharmacy
13.6.1.4.2. Hospital Pharmacy
13.6.2. The UK
13.6.2.1. The UK Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.2.1.1. Prescription Products
13.6.2.1.2. Over the Counter (OTC) Products
13.6.2.2. The UK Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.2.2.1. Respiratory
13.6.2.2.2. Dermatology
13.6.2.2.3. Oncology
13.6.2.2.4. Diabetes
13.6.2.2.5. Infectious diseases
13.6.2.2.6. Ophthalmology
13.6.2.2.7. Women’s Health
13.6.2.2.8. Central Nervous System (CNS)
13.6.2.2.9. Cardiovascular
13.6.2.2.10.
Urology
13.6.2.2.11.
Others
13.6.2.3. The UK Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
13.6.2.3.1. Tablets
13.6.2.3.2. Capsules
13.6.2.3.3. Injectables
13.6.2.3.4. Topical Creams
13.6.2.3.5. Others
13.6.2.4. The UK Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.2.4.1. Retail Pharmacy
13.6.2.4.2. Hospital Pharmacy
13.6.3. Spain
13.6.3.1. Spain Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.3.1.1. Prescription Products
13.6.3.1.2. Over the Counter (OTC) Products
13.6.3.2. Spain Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.3.2.1. Respiratory
13.6.3.2.2. Dermatology
13.6.3.2.3. Oncology
13.6.3.2.4. Diabetes
13.6.3.2.5. Infectious diseases
13.6.3.2.6. Ophthalmology
13.6.3.2.7. Women’s Health
13.6.3.2.8. Central Nervous System (CNS)
13.6.3.2.9. Cardiovascular
13.6.3.2.10.
Urology
13.6.3.2.11.
Others
13.6.3.3. Spain Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
13.6.3.3.1. Tablets
13.6.3.3.2. Capsules
13.6.3.3.3. Injectables
13.6.3.3.4. Topical Creams
13.6.3.3.5. Others
13.6.3.4. Spain Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.3.4.1. Retail Pharmacy
13.6.3.4.2. Hospital Pharmacy
13.6.4. Germany
13.6.4.1. Germany Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Type
13.6.4.1.1. Prescription Products
13.6.4.1.2. Over the Counter (OTC) Products
13.6.4.2. Germany Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Application
13.6.4.2.1. Respiratory
13.6.4.2.2. Dermatology
13.6.4.2.3. Oncology
13.6.4.2.4. Diabetes
13.6.4.2.5. Infectious diseases
13.6.4.2.6. Ophthalmology
13.6.4.2.7. Women’s Health
13.6.4.2.8. Central Nervous System (CNS)
13.6.4.2.9. Cardiovascular
13.6.4.2.10.
Urology
13.6.4.2.11.
Others
13.6.4.3. Germany Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Form
13.6.4.3.1. Tablets
13.6.4.3.2. Capsules
13.6.4.3.3. Injectables
13.6.4.3.4. Topical Creams
13.6.4.3.5. Others
13.6.4.4. Germany Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
13.6.4.4.1. Retail Pharmacy
13.6.4.4.2. Hospital Pharmacy
13.6.5. Italy
13.6.5.1. Italy Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.5.1.1. Prescription Products
13.6.5.1.2. Over the Counter (OTC) Products
13.6.5.2. Italy Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.5.2.1. Respiratory
13.6.5.2.2. Dermatology
13.6.5.2.3. Oncology
13.6.5.2.4. Diabetes
13.6.5.2.5. Infectious diseases
13.6.5.2.6. Ophthalmology
13.6.5.2.7. Women’s Health
13.6.5.2.8. Central Nervous System (CNS)
13.6.5.2.9. Cardiovascular
13.6.5.2.10.
Urology
13.6.5.2.11.
Others
13.6.5.3. Italy Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
13.6.5.3.1. Tablets
13.6.5.3.2. Capsules
13.6.5.3.3. Injectables
13.6.5.3.4. Topical Creams
13.6.5.3.5. Others
13.6.5.4. Italy Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.6.5.4.1. Retail Pharmacy
13.6.5.4.2. Hospital Pharmacy
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.6.1.1. Prescription Products
13.6.6.1.2. Over the Counter (OTC) Products
13.6.6.2. Nordic Countries Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.6.2.1. Respiratory
13.6.6.2.2. Dermatology
13.6.6.2.3. Oncology
13.6.6.2.4. Diabetes
13.6.6.2.5. Infectious diseases
13.6.6.2.6. Ophthalmology
13.6.6.2.7. Women’s Health
13.6.6.2.8. Central Nervous System (CNS)
13.6.6.2.9. Cardiovascular
13.6.6.2.10.
Urology
13.6.6.2.11.
Others
13.6.6.3. Nordic Countries Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.6.3.1. Tablets
13.6.6.3.2. Capsules
13.6.6.3.3. Injectables
13.6.6.3.4. Topical Creams
13.6.6.3.5. Others
13.6.6.4. Nordic Countries Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.6.4.1. Retail Pharmacy
13.6.6.4.2. Hospital Pharmacy
13.6.6.5. Nordic Countries Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.7.1.1. Prescription Products
13.6.7.1.2. Over the Counter (OTC) Products
13.6.7.2. Benelux Union Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.7.2.1. Respiratory
13.6.7.2.2. Dermatology
13.6.7.2.3. Oncology
13.6.7.2.4. Diabetes
13.6.7.2.5. Infectious diseases
13.6.7.2.6. Ophthalmology
13.6.7.2.7. Women’s Health
13.6.7.2.8. Central Nervous System (CNS)
13.6.7.2.9. Cardiovascular
13.6.7.2.10.
Urology
13.6.7.2.11.
Others
13.6.7.3. Benelux Union Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.7.3.1. Tablets
13.6.7.3.2. Capsules
13.6.7.3.3. Injectables
13.6.7.3.4. Topical Creams
13.6.7.3.5. Others
13.6.7.4. Benelux Union Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.7.4.1. Retail Pharmacy
13.6.7.4.2. Hospital Pharmacy
13.6.7.5. Benelux Union Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
13.6.8.1.1. Prescription Products
13.6.8.1.2. Over the Counter (OTC) Products
13.6.8.2. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.8.2.1. Respiratory
13.6.8.2.2. Dermatology
13.6.8.2.3. Oncology
13.6.8.2.4. Diabetes
13.6.8.2.5. Infectious diseases
13.6.8.2.6. Ophthalmology
13.6.8.2.7. Women’s Health
13.6.8.2.8. Central Nervous System (CNS)
13.6.8.2.9. Cardiovascular
13.6.8.2.10.
Urology
13.6.8.2.11.
Others
13.6.8.3. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
13.6.8.3.1. Tablets
13.6.8.3.2. Capsules
13.6.8.3.3. Injectables
13.6.8.3.4. Topical Creams
13.6.8.3.5. Others
13.6.8.4. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.8.4.1. Retail Pharmacy
13.6.8.4.2. Hospital Pharmacy
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By Type
13.7.3. By
Application
13.7.4. By Form
13.7.5. By
Distribution Channel
14. Asia Pacific Generic Drugs Market Analysis and Forecasts,
2019 - 2027
14.1. Overview
14.1.1. Asia
Pacific Generic Drugs Market Revenue (US$ Mn)
14.2. Asia
Pacific Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Prescription
Products
14.2.2. Over
the Counter (OTC) Products
14.3. Asia
Pacific Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1. Respiratory
14.3.2. Dermatology
14.3.3. Oncology
14.3.4. Diabetes
14.3.5. Infectious
diseases
14.3.6. Ophthalmology
14.3.7. Women’s
Health
14.3.8. Central
Nervous System (CNS)
14.3.9. Cardiovascular
14.3.10. Urology
14.3.11. Others
14.4. Asia
Pacific Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Form
14.4.1. Tablets
14.4.2. Capsules
14.4.3. Injectables
14.4.4. Topical
Creams
14.4.5. Others
14.5. Asia
Pacific Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.1. Retail
Pharmacy
14.5.2. Hospital
Pharmacy
14.6. Asia Pacific
Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.1.1.1. Prescription Products
14.6.1.1.2. Over the Counter (OTC) Products
14.6.1.2. China Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.1.2.1. Respiratory
14.6.1.2.2. Dermatology
14.6.1.2.3. Oncology
14.6.1.2.4. Diabetes
14.6.1.2.5. Infectious diseases
14.6.1.2.6. Ophthalmology
14.6.1.2.7. Women’s Health
14.6.1.2.8. Central Nervous System (CNS)
14.6.1.2.9. Cardiovascular
14.6.1.2.10.
Urology
14.6.1.2.11.
Others
14.6.1.3. China Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
14.6.1.3.1. Tablets
14.6.1.3.2. Capsules
14.6.1.3.3. Injectables
14.6.1.3.4. Topical Creams
14.6.1.3.5. Others
14.6.1.4. China Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.1.4.1. Retail Pharmacy
14.6.1.4.2. Hospital Pharmacy
14.6.2. Japan
14.6.2.1. Japan Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.2.1.1. Prescription Products
14.6.2.1.2. Over the Counter (OTC) Products
14.6.2.2. Japan Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.2.2.1. Respiratory
14.6.2.2.2. Dermatology
14.6.2.2.3. Oncology
14.6.2.2.4. Diabetes
14.6.2.2.5. Infectious diseases
14.6.2.2.6. Ophthalmology
14.6.2.2.7. Women’s Health
14.6.2.2.8. Central Nervous System (CNS)
14.6.2.2.9. Cardiovascular
14.6.2.2.10.
Urology
14.6.2.2.11.
Others
14.6.2.3. Japan Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
14.6.2.3.1. Tablets
14.6.2.3.2. Capsules
14.6.2.3.3. Injectables
14.6.2.3.4. Topical Creams
14.6.2.3.5. Others
14.6.2.4. Japan Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.2.4.1. Retail Pharmacy
14.6.2.4.2. Hospital Pharmacy
14.6.3. India
14.6.3.1. India Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.3.1.1. Prescription Products
14.6.3.1.2. Over the Counter (OTC) Products
14.6.3.2. India Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.3.2.1. Respiratory
14.6.3.2.2. Dermatology
14.6.3.2.3. Oncology
14.6.3.2.4. Diabetes
14.6.3.2.5. Infectious diseases
14.6.3.2.6. Ophthalmology
14.6.3.2.7. Women’s Health
14.6.3.2.8. Central Nervous System (CNS)
14.6.3.2.9. Cardiovascular
14.6.3.2.10.
Urology
14.6.3.2.11.
Others
14.6.3.3. India Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
14.6.3.3.1. Tablets
14.6.3.3.2. Capsules
14.6.3.3.3. Injectables
14.6.3.3.4. Topical Creams
14.6.3.3.5. Others
14.6.3.4. India Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.3.4.1. Retail Pharmacy
14.6.3.4.2. Hospital Pharmacy
14.6.4. New
Zealand
14.6.4.1. New Zealand Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.4.1.1. Prescription Products
14.6.4.1.2. Over the Counter (OTC) Products
14.6.4.2. New Zealand Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Application
14.6.4.2.1. Respiratory
14.6.4.2.2. Dermatology
14.6.4.2.3. Oncology
14.6.4.2.4. Diabetes
14.6.4.2.5. Infectious diseases
14.6.4.2.6. Ophthalmology
14.6.4.2.7. Women’s Health
14.6.4.2.8. Central Nervous System (CNS)
14.6.4.2.9. Cardiovascular
14.6.4.2.10.
Urology
14.6.4.2.11.
Others
14.6.4.3. New Zealand Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.4.3.1. Tablets
14.6.4.3.2. Capsules
14.6.4.3.3. Injectables
14.6.4.3.4. Topical Creams
14.6.4.3.5. Others
14.6.4.4. New Zealand Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.4.4.1. Retail Pharmacy
14.6.4.4.2. Hospital Pharmacy
14.6.5. Australia
14.6.5.1. Australia Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Type
14.6.5.1.1. Prescription Products
14.6.5.1.2. Over the Counter (OTC) Products
14.6.5.2. Australia Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Application
14.6.5.2.1. Respiratory
14.6.5.2.2. Dermatology
14.6.5.2.3. Oncology
14.6.5.2.4. Diabetes
14.6.5.2.5. Infectious diseases
14.6.5.2.6. Ophthalmology
14.6.5.2.7. Women’s Health
14.6.5.2.8. Central Nervous System (CNS)
14.6.5.2.9. Cardiovascular
14.6.5.2.10.
Urology
14.6.5.2.11.
Others
14.6.5.3. Australia Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Form
14.6.5.3.1. Tablets
14.6.5.3.2. Capsules
14.6.5.3.3. Injectables
14.6.5.3.4. Topical Creams
14.6.5.3.5. Others
14.6.5.4. Australia Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
14.6.5.4.1. Retail Pharmacy
14.6.5.4.2. Hospital Pharmacy
14.6.6. South
Korea
14.6.6.1. South Korea Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.6.1.1. Prescription Products
14.6.6.1.2. Over the Counter (OTC) Products
14.6.6.2. South Korea Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.6.2.1. Respiratory
14.6.6.2.2. Dermatology
14.6.6.2.3. Oncology
14.6.6.2.4. Diabetes
14.6.6.2.5. Infectious diseases
14.6.6.2.6. Ophthalmology
14.6.6.2.7. Women’s Health
14.6.6.2.8. Central Nervous System (CNS)
14.6.6.2.9. Cardiovascular
14.6.6.2.10.
Urology
14.6.6.2.11.
Others
14.6.6.3. South Korea Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.6.3.1. Tablets
14.6.6.3.2. Capsules
14.6.6.3.3. Injectables
14.6.6.3.4. Topical Creams
14.6.6.3.5. Others
14.6.6.4. South Korea Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.6.4.1. Retail Pharmacy
14.6.6.4.2. Hospital Pharmacy
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.7.1.1. Prescription Products
14.6.7.1.2. Over the Counter (OTC) Products
14.6.7.2. Southeast Asia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.7.2.1. Respiratory
14.6.7.2.2. Dermatology
14.6.7.2.3. Oncology
14.6.7.2.4. Diabetes
14.6.7.2.5. Infectious diseases
14.6.7.2.6. Ophthalmology
14.6.7.2.7. Women’s Health
14.6.7.2.8. Central Nervous System (CNS)
14.6.7.2.9. Cardiovascular
14.6.7.2.10.
Urology
14.6.7.2.11.
Others
14.6.7.3. Southeast Asia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.7.3.1. Tablets
14.6.7.3.2. Capsules
14.6.7.3.3. Injectables
14.6.7.3.4. Topical Creams
14.6.7.3.5. Others
14.6.7.4. Southeast Asia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.7.4.1. Retail Pharmacy
14.6.7.4.2. Hospital Pharmacy
14.6.7.5. Southeast Asia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
14.6.8.1.1. Prescription Products
14.6.8.1.2. Over the Counter (OTC) Products
14.6.8.2. Rest of Asia Pacific Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.8.2.1. Respiratory
14.6.8.2.2. Dermatology
14.6.8.2.3. Oncology
14.6.8.2.4. Diabetes
14.6.8.2.5. Infectious diseases
14.6.8.2.6. Ophthalmology
14.6.8.2.7. Women’s Health
14.6.8.2.8. Central Nervous System (CNS)
14.6.8.2.9. Cardiovascular
14.6.8.2.10.
Urology
14.6.8.2.11.
Others
14.6.8.3. Rest of Asia Pacific Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
14.6.8.3.1. Tablets
14.6.8.3.2. Capsules
14.6.8.3.3. Injectables
14.6.8.3.4. Topical Creams
14.6.8.3.5. Others
14.6.8.4. Rest of Asia Pacific Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.8.4.1. Retail Pharmacy
14.6.8.4.2. Hospital Pharmacy
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By Type
14.7.3. By
Application
14.7.4. By Form
14.7.5. By
Distribution Channel
15. Middle East and Africa Generic Drugs Market Analysis and
Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Middle
East and Africa Generic Drugs Market Revenue (US$ Mn)
15.2. Middle
East and Africa Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Prescription
Products
15.2.2. Over
the Counter (OTC) Products
15.3. Middle
East and Africa Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
15.3.1. Respiratory
15.3.2. Dermatology
15.3.3. Oncology
15.3.4. Diabetes
15.3.5. Infectious
diseases
15.3.6. Ophthalmology
15.3.7. Women’s
Health
15.3.8. Central
Nervous System (CNS)
15.3.9. Cardiovascular
15.3.10. Urology
15.3.11. Others
15.4. Middle
East and Africa Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Form
15.4.1. Tablets
15.4.2. Capsules
15.4.3. Injectables
15.4.4. Topical
Creams
15.4.5. Others
15.5. Middle
East and Africa Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.5.1. Retail
Pharmacy
15.5.2. Hospital
Pharmacy
15.6. Middle
East and Africa Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.1.1.1. Prescription Products
15.6.1.1.2. Over the Counter (OTC) Products
15.6.1.2. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.1.2.1. Respiratory
15.6.1.2.2. Dermatology
15.6.1.2.3. Oncology
15.6.1.2.4. Diabetes
15.6.1.2.5. Infectious diseases
15.6.1.2.6. Ophthalmology
15.6.1.2.7. Women’s Health
15.6.1.2.8. Central Nervous System (CNS)
15.6.1.2.9. Cardiovascular
15.6.1.2.10.
Urology
15.6.1.2.11.
Others
15.6.1.3. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
15.6.1.3.1. Tablets
15.6.1.3.2. Capsules
15.6.1.3.3. Injectables
15.6.1.3.4. Topical Creams
15.6.1.3.5. Others
15.6.1.4. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.1.4.1. Retail Pharmacy
15.6.1.4.2. Hospital Pharmacy
15.6.2. UAE
15.6.2.1. UAE Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.2.1.1. Prescription Products
15.6.2.1.2. Over the Counter (OTC) Products
15.6.2.2. UAE Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.2.2.1. Respiratory
15.6.2.2.2. Dermatology
15.6.2.2.3. Oncology
15.6.2.2.4. Diabetes
15.6.2.2.5. Infectious diseases
15.6.2.2.6. Ophthalmology
15.6.2.2.7. Women’s Health
15.6.2.2.8. Central Nervous System (CNS)
15.6.2.2.9. Cardiovascular
15.6.2.2.10.
Urology
15.6.2.2.11.
Others
15.6.2.3. UAE Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
15.6.2.3.1. Tablets
15.6.2.3.2. Capsules
15.6.2.3.3. Injectables
15.6.2.3.4. Topical Creams
15.6.2.3.5. Others
15.6.2.4. UAE Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.2.4.1. Retail Pharmacy
15.6.2.4.2. Hospital Pharmacy
15.6.3. Egypt
15.6.3.1. Egypt Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.3.1.1. Prescription Products
15.6.3.1.2. Over the Counter (OTC) Products
15.6.3.2. Egypt Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.3.2.1. Respiratory
15.6.3.2.2. Dermatology
15.6.3.2.3. Oncology
15.6.3.2.4. Diabetes
15.6.3.2.5. Infectious diseases
15.6.3.2.6. Ophthalmology
15.6.3.2.7. Women’s Health
15.6.3.2.8. Central Nervous System (CNS)
15.6.3.2.9. Cardiovascular
15.6.3.2.10.
Urology
15.6.3.2.11.
Others
15.6.3.3. Egypt Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
15.6.3.3.1. Tablets
15.6.3.3.2. Capsules
15.6.3.3.3. Injectables
15.6.3.3.4. Topical Creams
15.6.3.3.5. Others
15.6.3.4. Egypt Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.6.3.4.1. Retail Pharmacy
15.6.3.4.2. Hospital Pharmacy
15.6.4. Kuwait
15.6.4.1. Kuwait Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.4.1.1. Prescription Products
15.6.4.1.2. Over the Counter (OTC) Products
15.6.4.2. Kuwait Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.4.2.1. Respiratory
15.6.4.2.2. Dermatology
15.6.4.2.3. Oncology
15.6.4.2.4. Diabetes
15.6.4.2.5. Infectious diseases
15.6.4.2.6. Ophthalmology
15.6.4.2.7. Women’s Health
15.6.4.2.8. Central Nervous System (CNS)
15.6.4.2.9. Cardiovascular
15.6.4.2.10.
Urology
15.6.4.2.11.
Others
15.6.4.3. Kuwait Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
15.6.4.3.1. Tablets
15.6.4.3.2. Capsules
15.6.4.3.3. Injectables
15.6.4.3.4. Topical Creams
15.6.4.3.5. Others
15.6.4.4. Kuwait Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.6.4.4.1. Retail Pharmacy
15.6.4.4.2. Hospital Pharmacy
15.6.5. South
Africa
15.6.5.1. South Africa Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Type
15.6.5.1.1. Prescription Products
15.6.5.1.2. Over the Counter (OTC) Products
15.6.5.2. South Africa Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.5.2.1. Respiratory
15.6.5.2.2. Dermatology
15.6.5.2.3. Oncology
15.6.5.2.4. Diabetes
15.6.5.2.5. Infectious diseases
15.6.5.2.6. Ophthalmology
15.6.5.2.7. Women’s Health
15.6.5.2.8. Central Nervous System (CNS)
15.6.5.2.9. Cardiovascular
15.6.5.2.10.
Urology
15.6.5.2.11.
Others
15.6.5.3. South Africa Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Form
15.6.5.3.1. Tablets
15.6.5.3.2. Capsules
15.6.5.3.3. Injectables
15.6.5.3.4. Topical Creams
15.6.5.3.5. Others
15.6.5.4. South Africa Generic Drugs Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.5.4.1. Retail Pharmacy
15.6.5.4.2. Hospital Pharmacy
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Generic Drugs Market Revenue
(US$ Mn) and Forecasts, By Type
15.6.6.1.1. Prescription Products
15.6.6.1.2. Over the Counter (OTC) Products
15.6.6.2. Rest of Middle East & Africa Generic Drugs Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.6.2.1. Respiratory
15.6.6.2.2. Dermatology
15.6.6.2.3. Oncology
15.6.6.2.4. Diabetes
15.6.6.2.5. Infectious diseases
15.6.6.2.6. Ophthalmology
15.6.6.2.7. Women’s Health
15.6.6.2.8. Central Nervous System (CNS)
15.6.6.2.9. Cardiovascular
15.6.6.2.10.
Urology
15.6.6.2.11.
Others
15.6.6.3. Rest of Middle East & Africa Generic Drugs Market Revenue
(US$ Mn) and Forecasts, By Form
15.6.6.3.1. Tablets
15.6.6.3.2. Capsules
15.6.6.3.3. Injectables
15.6.6.3.4. Topical Creams
15.6.6.3.5. Others
15.6.6.4. Rest of Middle East & Africa Generic Drugs Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
15.6.6.4.1. Retail Pharmacy
15.6.6.4.2. Hospital Pharmacy
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Type
15.7.3. By
Application
15.7.4. By Form
15.7.5. By
Distribution Channel
16. Latin America Generic Drugs Market Analysis and Forecasts,
2019 - 2027
16.1. Overview
16.1.1. Latin
America Generic Drugs Market Revenue (US$ Mn)
16.2. Latin
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Prescription
Products
16.2.2. Over
the Counter (OTC) Products
16.3. Latin
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Application
16.3.1. Respiratory
16.3.2. Dermatology
16.3.3. Oncology
16.3.4. Diabetes
16.3.5. Infectious
diseases
16.3.6. Ophthalmology
16.3.7. Women’s
Health
16.3.8. Central
Nervous System (CNS)
16.3.9. Cardiovascular
16.3.10. Urology
16.3.11. Others
16.4. Latin
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Form
16.4.1. Tablets
16.4.2. Capsules
16.4.3. Injectables
16.4.4. Topical
Creams
16.4.5. Others
16.5. Latin
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
16.5.1. Retail
Pharmacy
16.5.2. Hospital
Pharmacy
16.6. Latin
America Generic Drugs Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Type
16.6.1.1.1. Prescription Products
16.6.1.1.2. Over the Counter (OTC) Products
16.6.1.2. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.1.2.1. Respiratory
16.6.1.2.2. Dermatology
16.6.1.2.3. Oncology
16.6.1.2.4. Diabetes
16.6.1.2.5. Infectious diseases
16.6.1.2.6. Ophthalmology
16.6.1.2.7. Women’s Health
16.6.1.2.8. Central Nervous System (CNS)
16.6.1.2.9. Cardiovascular
16.6.1.2.10.
Urology
16.6.1.2.11.
Others
16.6.1.3. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Form
16.6.1.3.1. Tablets
16.6.1.3.2. Capsules
16.6.1.3.3. Injectables
16.6.1.3.4. Topical Creams
16.6.1.3.5. Others
16.6.1.4. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.6.1.4.1. Retail Pharmacy
16.6.1.4.2. Hospital Pharmacy
16.6.2. Argentina
16.6.2.1. Argentina Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Type
16.6.2.1.1. Prescription Products
16.6.2.1.2. Over the Counter (OTC) Products
16.6.2.2. Argentina Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Application
16.6.2.2.1. Respiratory
16.6.2.2.2. Dermatology
16.6.2.2.3. Oncology
16.6.2.2.4. Diabetes
16.6.2.2.5. Infectious diseases
16.6.2.2.6. Ophthalmology
16.6.2.2.7. Women’s Health
16.6.2.2.8. Central Nervous System (CNS)
16.6.2.2.9. Cardiovascular
16.6.2.2.10.
Urology
16.6.2.2.11.
Others
16.6.2.3. Argentina Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Form
16.6.2.3.1. Tablets
16.6.2.3.2. Capsules
16.6.2.3.3. Injectables
16.6.2.3.4. Topical Creams
16.6.2.3.5. Others
16.6.2.4. Argentina Generic Drugs Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.6.2.4.1. Retail Pharmacy
16.6.2.4.2. Hospital Pharmacy
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Type
16.6.3.1.1. Prescription Products
16.6.3.1.2. Over the Counter (OTC) Products
16.6.3.2. Rest of Latin America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Application
16.6.3.2.1. Respiratory
16.6.3.2.2. Dermatology
16.6.3.2.3. Oncology
16.6.3.2.4. Diabetes
16.6.3.2.5. Infectious diseases
16.6.3.2.6. Ophthalmology
16.6.3.2.7. Women’s Health
16.6.3.2.8. Central Nervous System (CNS)
16.6.3.2.9. Cardiovascular
16.6.3.2.10.
Urology
16.6.3.2.11.
Others
16.6.3.3. Rest of Latin America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Form
16.6.3.3.1. Tablets
16.6.3.3.2. Capsules
16.6.3.3.3. Injectables
16.6.3.3.4. Topical Creams
16.6.3.3.5. Others
16.6.3.4. Rest of Latin America Generic Drugs Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
16.6.3.4.1. Retail Pharmacy
16.6.3.4.2. Hospital Pharmacy
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By Type
16.7.3. By
Application
16.7.4. By Form
16.7.5. By
Distribution Channel
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2018
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Abbott Laboratories
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Allergan, Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Alvion Pharmaceuticals P.C.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Amneal Pharmaceuticals, Inc
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Aspen Pharmacare Holdings Limited.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. AstraZeneca plc
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Cipla Inc.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Dr. Reddy’s Laboratories Ltd
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Egis Group
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Eli Lilly and Company
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Endo International plc
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Fresenius Kabi (Kabi SwissBioSim GmbH)
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Gedeon Richter Ltd
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Gilead Sciences, Inc.
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. GlaxoSmithKline Plc.
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Lupin Pharmaceuticals, Inc
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. Mylan N.V.
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Novartis International AG
18.18.1. Company Details
18.18.2. Company Overview
18.18.3. Product Offerings
18.18.4. Key Developments
18.18.5. Financial Analysis
18.18.6. SWOT Analysis
18.18.7. Business Strategies
18.19. Pfizer Inc
18.19.1. Company Details
18.19.2. Company Overview
18.19.3. Product Offerings
18.19.4. Key Developments
18.19.5. Financial Analysis
18.19.6. SWOT Analysis
18.19.7. Business Strategies
18.20. STADA Arzneimittel AG
18.20.1. Company Details
18.20.2. Company Overview
18.20.3. Product Offerings
18.20.4. Key Developments
18.20.5. Financial Analysis
18.20.6. SWOT Analysis
18.20.7. Business Strategies
18.21. Sun Pharmaceutical Industries
18.21.1. Company Details
18.21.2. Company Overview
18.21.3. Product Offerings
18.21.4. Key Developments
18.21.5. Financial Analysis
18.21.6. SWOT Analysis
18.21.7. Business Strategies
18.22. Teva Pharmaceutical Industries Ltd.
18.22.1. Company Details
18.22.2. Company Overview
18.22.3. Product Offerings
18.22.4. Key Developments
18.22.5. Financial Analysis
18.22.6. SWOT Analysis
18.22.7. Business Strategies
18.23. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
